Creative BioMart can offer development services for TCRm antibodies targeting the pMHC complex, offering customers worldwide a one-stop development solution from cancer-related pMHC antigen selection, TCRm antibody design and production to validation, evaluation, and optimization.

TCRm Antibody and MHC Complex

The pMHC complex is not a single protein, it consists of MHC molecules and peptides derived from tumor-associated antigens. The natural conformation of the pMHC complex is essential for the screening and isolation of TCRm antibodies, and recombinant pMHC complex technology can facilitate the development of TCRm antibodies.

Natural TCRm antibodies are rare, and strategies for engineering TCRm antibodies for development have continued to improve in response to the growing library of tumor and viral antigens. Immunization and hybridoma, as well as in vitro screening by phage display, are the primary methods for TCRm antibody production and isolation.

Fig.1 Process flow chart for pMHC complex preparation and TCRm antibody development (Duan, Z and Ho, M, 2021)

Our Services

• pMHC Antigen Discovery and Design. Intracellular proteins can be processed and produce short peptides to form pMHC complexes that are presented on the cell surface. pMHC complexes can act as tumor-associated antigens targeted by TCRm antibodies. We offer solutions to develop antibodies to target these pMHC complexes, select immunotherapeutic targets and design immunogens by identifying and measuring tumor-associated antigenic epitopes.
• pMHC-targeted TCRm Antibody Design and Generation. Once the target is identified, the design and production of TCRm antibodies is an important next step. We offer design and production services for TCRm antibodies targeting pMHC, including not only recombinant development of MHC molecules for antibody screening, but also engineering services for antibody generation, allowing researchers to truly select antibodies with specificity and MHC restriction.
• pMHC-targeted TCRm Antibody Assessment and Validation. In order to advance the development of TCRm antibodies targeting novel MHC-restricted peptides, their specificity and biological activity should be validated. We provide multiple techniques to validate the cross-reactivity and specificity of TCRm antibodies targeting pMHC to achieve superior anti-tumor efficacy and safety so that TCRm antibodies can be used in future clinics as soon as possible.
• pMHC-targeted TCRm Antibody Optimization. The development of pMHC-targeted TCRm antibodies is hampered by the fact that they are MHC-restricted, occurrence of immune evasion and the immunosuppressive environment. In order for TCRm antibodies to achieve clinical success, we need to overcome these obstacles and optimize TCRm antibodies for ideal cancer immunotherapy. We provide optimization solutions for TCRm antibodies to enhance the potency of TCRm antibodies and maximize their benefits in subsequent applications.

Problems Solved

• Production of pMHC complexes
• Cross-reactivity of TCRm antibodies
• Low epitope density of pMHC complexes on the cell surface
• MHC restriction of TCRm antibody

TCRm antibodies have broad therapeutic potential in targeting intracellular proteins. Creative BioMart offers many efforts to improve pMHC antigen production and develop specific TCRm antibodies, including TCRm antibodies against more existing and new antigens.

We look forward to your innovative project, contact us to promote it.

Reference

• Duan, Z and Ho, M. "T-Cell Receptor Mimic Antibodies for Cancer Immunotherapy." Molecular cancer therapeutics (2021), 20(9): 1533-1541.